Alexander Kel
Overview
Explore the profile of Alexander Kel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez-Sosa A, Lawal O, McDonnell C, Grant L, OBrien J, Ali M, et al.
Gastro Hep Adv
. 2025 Feb;
4(3):100586.
PMID: 39944929
Background And Aims: Primary sclerosing cholangitis (PSC) is a progressive cholestatic disease with up to 80% of patients also suffering from ulcerative colitis (PSC-UC). The difficulty in the diagnosis along...
2.
Targeting fibroblast phenotype switching in cardiac remodelling as a promising antifibrotic strategy
Kel A, Thum T, Kunduzova O
Eur Heart J
. 2024 Nov;
46(4):354-358.
PMID: 39582108
Myocardial fibrosis, a common feature of heart disease, remains an unsolved clinical challenge. Fibrosis resolution requires activation of cardiac fibroblasts exhibiting context-dependent beneficial and detrimental dichotomy. Here, we explored the...
3.
Kisakol B, Matveeva A, Salvucci M, Kel A, McDonough E, Ginty F, et al.
Br J Cancer
. 2024 Mar;
130(11):1809-1818.
PMID: 38532103
Background: Existing colorectal cancer subtyping methods were generated without much consideration of potential differences in expression profiles between colon and rectal tissues. Moreover, locally advanced rectal cancers at resection often...
4.
Finnegan E, Ding W, Ude Z, Terer S, McGivern T, Blumel A, et al.
Cell Oncol (Dordr)
. 2023 Nov;
47(2):533-553.
PMID: 37934338
Purpose: The histone deacetylase inhibitor (HDACi), belinostat, has had limited therapeutic impact in solid tumors, such as colon cancer, due to its poor metabolic stability. Here we evaluated a novel...
5.
Biswas A, Salvucci M, Connor K, Dussmann H, Carberry S, Fichtner M, et al.
J Neurooncol
. 2023 May;
163(2):327-338.
PMID: 37237151
Background: Glioblastoma (GBM) is an aggressive brain cancer that typically results in death in the first 15 months after diagnosis. There have been limited advances in finding new treatments for...
6.
Myer P, Kim H, Blumel A, Finnegan E, Kel A, Thompson T, et al.
Gastro Hep Adv
. 2022 Jun;
1(3):328-341.
PMID: 35711675
Background And Aims: Individuals of African (AFR) ancestry have a higher incidence of colorectal cancer (CRC) than those of European (EUR) ancestry and exhibit significant health disparities. Previous studies have...
7.
Kolpakov F, Akberdin I, Kiselev I, Kolmykov S, Kondrakhin Y, Kulyashov M, et al.
Nucleic Acids Res
. 2022 May;
50(W1):W124-W131.
PMID: 35536253
BioUML (https://www.biouml.org)-is a web-based integrated platform for systems biology and data analysis. It supports visual modelling and construction of hierarchical biological models that allow us to construct the most complex...
8.
Sabatier P, Beusch C, Saei A, Aoun M, Moruzzi N, Coelho A, et al.
Nat Commun
. 2021 Nov;
12(1):6558.
PMID: 34772928
Detailed characterization of cell type transitions is essential for cell biology in general and particularly for the development of stem cell-based therapies in regenerative medicine. To systematically study such transitions,...
9.
Klopot A, Baida G, Kel A, Tsoi L, Perez White B, Budunova I
J Invest Dermatol
. 2021 Nov;
142(5):1360-1371.e15.
PMID: 34757068
Differences in the morphology and physiology of darkly pigmented skin compared with those of lightly pigmented skin are well-recognized. There are also disparities in the prevalence and clinical features for...
10.
Kalya M, Kel A, Wlochowitz D, Wingender E, Beissbarth T
Front Genet
. 2021 Jul;
12:670240.
PMID: 34211498
Only 2% of glioblastoma multiforme (GBM) patients respond to standard therapy and survive beyond 36 months (long-term survivors, LTS), while the majority survive less than 12 months (short-term survivors, STS)....